December 2018 Drug and Device Corner
Guidance Document updates on the FDA website All centers: Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products CDER: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing...November 2018 Drug and Device Corner
Guidance Document updates on the FDA website: All centers: Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA Guidance for IndustryOn December 3, 2018, the U.S. Food and Drug Administration (FDA) published the guidance for industry...Mutual Recognition Agreements for Monitoring US Drug Supply Written for Tablets & Capsules
James Evans expanded on his September 2018 issue of the month article on MRAs in an article published in Tablets and Capsules magazine. He discusses MRAs in-depth, as well as Field Action Reports, Med-Watch Reports, and Drug Quality Sampling and Testing as methods of...Pharma’s Problems with Data Integrity
FDA takes data Integrity very seriously and their many Warning Letters and Import Alerts to dosage form and Active Pharmaceutical Ingredient (API) manufacturers in the past several years, indicate that validation is a consistent problem for the pharmaceutical industry. Data integrity, or lack thereof …